Can grid radiation revive immunotherapy in lung cancer?

NCT ID NCT05443971

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested whether combining the immunotherapy drug durvalumab with a special type of radiation called grid therapy could help people with non-small cell lung cancer whose cancer had stopped responding to durvalumab alone. Only 4 patients were enrolled before the study was stopped early. The main goal was to check safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (Imfinzi) and grid radiation therapy
What this could lead to: If it works, this could point toward a way to restore immunotherapy effectiveness in lung cancer patients who have stopped responding.
What could go wrong: This was a very small pilot study (only 4 patients) that was terminated early, so results are limited and may not apply to others. The combination also carries risks of immune-related side effects and radiation damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NON-SMALL CELL CARCINOMA STAGE III LUNG CANCER AJCC V8

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.